Rick Labuda, Executive Director & Secretary
Mr. Labuda is the Founder of Conquer Chiari. As a Chiari patient himself, he knows firsthand the pain and frustration of dealing with this disease. He has written hundreds of articles on Chiari and related topics; is the author of "Conquer Chiari: A Patients Guide to Chiari Malformation" and is co-author of several peer reviewed scientific publications. Mr. Labuda holds a BS in Electrical Engineering from Carnegie Mellon and has over 20 years of business experience across a range of industries and disciplines.
Rich Kushner, President & Director
Mr. Kushner is Vice President, Sales & Marketing for Modern Transportation Systems and has over 25 years of business and marketing experience in industries ranging from aerospace to telecommunication/Internet to software and logistics. Mr. Kushner is active in the non-profit sector and is a Director of the American Respiratory Alliance. He holds a Master's in Management and Policy Analysis from Carnegie Mellon University.
David Lee, Vice President & Director
Mr. Lee is a business and high technology professional with 25 years of experience across a variety of industries and vocations. Currently he is a Product Manager at Dynavox, a manufacturer of communications products which assist individuals in overcoming speech, language and learning challenges. He is an expert in the application of cutting edge technology to innovative business practices. Mr. Lee holds a degree in Business from Boston University.
Mark Tomczak, Treasurer & Director
Mr. Tomczak is a Certified Public Accountant (CPA) with over 25 years of world-wide, financial management experience, including 6 years at Price Waterhouse. Mr. Tomczak is currently Chief Financial Officer at Inmedius, a Boeing Company a global leader in delivering innovative, performance-oriented applications and services that capture, create, manage and deploy technical information assets.
Mr. O’Hanlon is the President and CEO of Celsense, Inc., a biotechnology company offering novel molecular imaging agents used to diagnose disease and discover new therapeutics. Prior to Celsense, Mr. O’Hanlon was a Managing Director of Cornerstone Capital Advisors Ltd., a consultancy based in Pittsburgh, Pennsylvania. While at Cornerstone, he provided strategic advice and corporate finance services to midsized and family owned businesses, and expert testimony in complex litigation. Prior to Cornerstone, Mr. O’Hanlon spent 29 years in commercial banking and financial services, holding executive positions at National City Bank and Mellon Bank. Mr. O’Hanlon currently serves on the Board of Directors and as Secretary/Treasurer of City of Asylum, an organization providing sanctuary to persecuted writers. He previously has served as a Director of multiple privately held corporations and non-profit organizations. Mr. O’Hanlon is a 1975 graduate of the Georgia Institute of Technology. He studied Operations Research and received a BS in Industrial Management. He received an MBA from Robert Morris College in 1980. Mr. O’Hanlon is a co-author of several scientific papers and an invited speaker in the fields of molecular imaging, cellular therapeutics, and business insolvency.
Dr. Diane Mueller, Director Emeritus
Dr. Mueller achieved her Doctorate in Nursing from Case Western Reserve University and has over 25 years of neurosurgical nursing experience. She is currently working with Dr Oro at the Chiari Care Center in Aurora Colorado. During her career has treated hundreds of Chiari and syringomyelia patients. Dr Mueller has authored multiple publications in peer reviewed journals and is currently active in several research projects.
In order to remain independent, and adhere to our policy of not aligning with a specific doctor or hospital, Conquer Chiari does not have a formal medical or scientific advisory board. However, Conquer Chiari has built an extensive network of contacts with the medical and scientific leaders in the world wide Chiari community, and consults with these experts on an ongoing, as needed basis. Since we provide significant research funding, we believe that it is important to maintain a constructive, but arms length, relationship with the medical and scientific community in order to avoid conflicts of interest.